GTC Biotherapeutics (fka GTCB)

[shears]

If Atryn is priced lower than plasma derived ATIII then one would assume a pressure on hospital formularies to stock the lower priced and 'safer' version and substitute it whenever the plasma product is prescribed? Just a thought. I know hospitals do that all the time in the US for conventional drugs. Why not for Atryn? Just thinking out loud, but it makes sense to me that hospitals in EU face the same economic pressures. Also, as data starts coming out on aquired AT deficiency more off label use may ensue. I'm thinking if plasma derived ATIII is currently used in aquired deficiency states Atryn (particularly if less costly) might be substituted. Perhaps just wishful thinking. Does anyone have access to the plasma derived ATIII list of indications?